NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Niki BioSolutions, Inc. (NIKI) Stock Analysis

Niki BioSolutions, Inc. (NIKI) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

NIKI

$2.00

−$0.03 (−1.48%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare NIKI with… →

NIKI Key Statistics

As of Oct 21, 2026
Trading
Open
$1.86
Previous Close
$2.03
Day's Range
1.83–2.10
52-Week Range
1.83–17.20
Volume
10.55K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
−1.00
Valuation
Market Cap
$6.24M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−2.90
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$1.36M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
2.94M
1-Year Return
−87.50%
Dividend and dates
Avg Volume
144.15K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, NIKI closed at $2.00, −87.50% over 1 year.

Niki BioSolutions, Inc. (NIKI) has a market capitalization of $6.24M.

In fiscal 2025, NIKI reported revenue of $0.00.

NIKI Stock Return by Calendar Year

Niki BioSolutions, Inc. (NIKI) return since Dec 2018: what $10,000 became

1 year
$10,000 $1,250
−87.50%
5 years
$10,000 $80
−99.20%
Since Dec 2018
$10,000 $14
−99.86%

If you had invested $10,000 in Niki BioSolutions, Inc. (NIKI) at the close on December 18, 2018, the earliest close on record here, it would have been worth $14 at the close on October 21, 2026: −99.86% in total, −56.77% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−81.13%
2025−62.14%
2024+14.33%
2023−55.47%
2022−63.33%
2021−39.27%
2020−84.42%
2019+4.41%
2018 (partial year)+5.78%

As of October 21, 2026.

NIKI Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$1.36M—
2024$0.00−$4.27M—
2023$431.38K−$2.82M−654.8%
2022$1.30M−$9.80M−756.2%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00$0.00−$1.82M−$1.36M—
2024$0.00$0.00−$3.00M−$4.27M—
2023$431.38K$10.57K−$10.60M−$2.82M−654.8%
2022$1.30M$80.07K−$17.17M−$9.80M−756.2%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

All 7 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Niki BioSolutions, Inc. (NIKI) carries a market capitalisation of $6.24M. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 1.

The most recent close on file for NIKI is $2.00, dated October 21, 2026. That is −$0.03 (−1.48%) against the previous close. The 52-week range on file runs from $1.83 to $17.20. The latest close sits 9.29% above that 52-week low.

Financial Health

In fiscal 2025, Niki BioSolutions, Inc. reported revenue of $0.00. The same year closed with a net loss of $1.36M. Earnings per share on a trailing basis come to −2.9.

Across the 4 fiscal years on file, revenue moves from $1.30M in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

Over the trailing twelve months the total return is −87.50%. Measured over 5 years, that is −61.93% a year compounded. The reported beta is −1. Daily returns over the trailing 7 years annualize to a volatility of 283.92%.

Growth & Income

No dividend is on file for NIKI.

The strongest complete calendar year on file is 2024 at +14.33%; the weakest is 2020 at −84.42%. Of the 7 complete calendar years on file, 2 finished higher. So far in 2026 the total return is −81.13%.

Peer Comparison

Niki BioSolutions, Inc. (NIKI) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Niki BioSolutions, Inc. NIKI $6.24M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Niki BioSolutions, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Niki BioSolutions, Inc.

Niki BioSolutions, Inc., through its subsidiaries, operates as a clinical-stage biopharmaceutical company and engages in the discovery, development, and commercialization of therapeutic products to treat oncology and infectious diseases. Its pipeline products include SACT-1, a repurposed drug candidate, which is in a Phase 1 clinical trial to treat neuroblastoma and other cancer types; ALS-4, a repurposed small molecule, which is in a Phase 1 clinical trial for the treatment of bacterial infections, such as staphylococcus aureus, mycobacterium tuberculosis, and pseudomonas aeruginosa. The company also develops SACT-COV19, a repurposed small molecule, which is in a preclinical trial for the treatment of coronavirus disease; SACT-2 and SACT-3; ALS-1, a small molecule, which is in a preclinical trial to treat bacterial infections caused by staphylococcus aureus, including methicillin-resistant staphylococcus aureus (MRSA); and ALS-2/3, a small molecule, which is in a preclinical trial for the treatment of gram+ve bacterial infections. The company was formerly known as Aptorum Group Limited and changed its name to Niki BioSolutions, Inc. in July 2026. Niki BioSolutions, Inc. was incorporated in 2010 and is headquartered in Princeton, New Jersey. Niki BioSolutions, Inc. operates as a subsidiary of Jurchen Investment Corporation.

Visit website →